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Background:  Viral myocarditis may follow a rapidly progressive and fatal course
in children. Mechanical circulatory support may be a life-saving measure by allow-
ing an interval for return of native ventricular function in the majority of these
patients or by providing a bridge to transplantation in the remainder.
Methods:  A retrospective chart review of 15 children with viral myocarditis sup-
ported with extracorporeal membrane oxygenation (12 patients) or ventricular assist
devices (3 patients) was performed.
Results: All patients had histories and clinical findings consistent with acute
myocarditis. The median age was 4.6 years (range 1 day–13.6 years) with a medi-
an duration of mechanical circulatory support of 140 hours (range 48-400 hours).
Myocardial biopsy tissue demonstrated inflammatory infiltrates or necrosis, or
both, in 8 (67%) of the 12 patients who had biopsies. Overall survival was 12 (80%)
of 15 patients, with 10 (83%) survivors of extracorporeal membrane oxygenation
and 2 (67%) survivors of ventricular assist device support. Nine (60%) of the 15
patients were weaned from support, with 7 (78%) survivors; the remaining 6
patients were successfully bridged to transplantation, with 5 (83%) survivors. All
survivors not undergoing transplantation are currently alive with normal ventricular
function after a median follow-up of 1.1 years (range 0.9-5.3 years).
Conclusion: Eighty-percent of the children who required mechanical circulatory
support for acute myocarditis survived in this series. Recovery of native ventricular
function to allow weaning from support can be anticipated in many of these patients
with excellent prospects for eventual recovery of full myocardial function.
Asubset of patients with acute myocarditis has a rapidly progressivecourse of fulminant clinical deterioration that results in refractorycardiorespiratory failure despite maximal medical therapy.Because of the reversibility of the ventricular dysfunctionobserved during the course of this disease in some patients andthe option of cardiac transplantation for those whose ventricular
function does not recover, aggressive measures to support these patients during the
acute phase of their illness are justified.1-3 This report describes the successful use
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of mechanical circulatory support with extracorporeal mem-
brane oxygenation (ECMO) or ventricular assist devices
(VADs) to support children with clinically fulminant
myocarditis and profound ventricular dysfunction.
Providing mechanical circulatory support until native ven-
tricular function returns may be a successful strategy in the
majority of these patients.
Methods
Patients and Institutions 
A retrospective chart review of 15 children from 3 institutions
(Children’s Hospital, Boston; Hospital for Sick Children, Toronto;
and Children’s Hospital and Regional Medical Center, Seattle) was
performed. This represents a consecutive series of children from
each institution who required mechanical circulatory support for
acute myocarditis over an 8-year period (1990-1997). These 15
patients represent 14.7% of the 102 patients who required admission
to the intensive care unit for acute myocarditis at the 3 study institu-
tions during the same period. The mortality for patients with acute
myocarditis who did not require mechanical circulatory support was
3 of 87 or 3.4%. Each of these 15 patients had profound, rapidly pro-
gressive ventricular dysfunction with a clinical picture compatible
with acute fulminant myocarditis and had mechanical circulatory
support instituted with ECMO or a VAD because of clinical deterio-
ration accompanied by imminently lethal cardiogenic shock or car-
diac arrest. Each patient was intubated and received conventional
mechanical ventilation before the institution of mechanical support.
The inotropic regimen these patients received at the time support
was instituted and 24 hours later is listed in Table 1. The single
patient (patient 10, Table 1) who was not receiving continuous infu-
sions of high-dose inotropic agents was in cardiac arrest on admis-
sion and was receiving boluses of inotropic drugs while receiving
cardiopulmonary resuscitation throughout cannulation.
Details of Support
We4 have previously described the technical aspects of mechani-
cal circulatory support for children with cardiac disease, which is
similar for all 3 institutions. The ECMO circuit used a servoreg-
ulated flow system driven by a roller pump (Boston, Seattle) or a
centrifugal pump (Bio-Pump; Medtronic Bio-Medicus,
Minneapolis, Minn) (Toronto) with a membrane oxygenator
(Avecor ECMO Membrane Oxygenator; Avecor Cardiovascular,
Inc, Plymouth, Minn). VAD support was provided by a centrifu-
gal pump system (Bio-Pump; Medtronic Bio-Medicus). Twelve
of the 15 patients were supported with venoarterial ECMO via
vessels in the neck (n = 3), groin (n = 3), or chest (n = 6). The
remaining 3 patients received VAD support; two were supported
with a left VAD and 1 patient required biventricular support. All
6 patients supported with ECMO via chest cannulation required
left heart decompression that was performed with direct place-
ment of a left ventricular vent via the sternotomy. One ECMO-
supported patient who was cannulated via peripheral vessels
required left heart decompression that was accomplished by cre-
ation of an interatrial communication by balloon atrial septosto-
my in the cardiac catheterization laboratory.
Statistical Analysis
Multiple clinical parameters were analyzed with respect to their possi-
ble impact on recovery of native ventricular function versus the need
for transplantation. The same parameters were then analyzed for their
TABLE 1. Clinical features of patients
Inotropic agents Inotropic agents at Indication for Listed for
Patient before support 24 h of support support transplantation? Outcome
1 Epi 1 DA 10, Am 10, NTG 0.5 Cardiac arrest Yes T, S
2 DA 2.5, Am 5 DA 2.5, Am 7 Arrhythmia Yes T, S
3 DA 15, DB 15, Am 5 DA 10, DB 7.5 Arrhythmia Yes W, S
4 DB 12, Epi 0.3, DB 12 Hypotension Yes W, S
Norepi 0.4
5 DA 20, DB 5, Epi 0.75 DA 10, DB 7.5 Hypotension No W, S
6 DB 20, Epi 0.15, None Hypoxemia Yes W, S
NTP 0.6
7 DA 20, DB 20, Am 20 DA 5, DB 3, Am 5 Hypotension No W, S
8 DA 5, DB 15, Epi 0.09, DA 15, DB 5, Am 10, Hypotension Yes T, S
Am 10 NTP 2
9 DA 15, DB 20, Epi 0.10 DA 3 Hypotension Yes T, NS
10 None DA 15, Am 10, NTP 2 Cardiac arrest Yes W, S
11 DA 10, DB 20, Am 5 DA 5, NTP 4 Cardiac arrest No W, S
12 DA 15, Epi 0.5 DA 5 Arrhythmia No W, NS
13 DA 7.5, DB 7.5 DA 5 Cardiac arrest Yes T, S
14 DA 15 DB 15, NTP 1 Arrhythmia No W, NS
15 DA 15, Epi 0.5, Am 7.5, NTP 3 Arrhythmia Yes T, S
NTP 1
All inotropic dosages are expressed in micrograms per kilogram per minute. Epi, Epinephrine; DA, dopamine; DB, dobutamine; Am, amrinone; Norepi, nor-
epinephrine; NTP, sodium nitroprusside; NTG, nitroglycerin. For outcomes: T, Transplanted; W, weaned from mechanical support; S, survivor; NS, nonsurvivor.
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possible association with survival (appendix). All variables were ana-
lyzed by univariate analysis with the Student t test or the Wilcoxon
rank sums for continuous variables and the Fisher exact test for cate-
gorical variables. All statistical analyses were performed with a statis-
tical program (JMP Software; SAS Institute, Inc, Cary, NC).
Results
General 
The patients included 7 girls and 8 boys with a median age
of 4.6 years (range 1 day–13.6 years) and a median weight
of 22 kg (range 5.2-55 kg). The median duration of support
was 140 hours (range 48-400 hours). The duration of symp-
toms before presentation was brief with a median duration
of 3 days (range 1-14 days).
Indications 
The indications for support were hypotension (n = 5),
arrhythmia (n = 5), cardiac arrest (n = 4), and hypoxemia (n
= 1) (Table 1). The 4 patients who required support for car-
diac arrest underwent cardiopulmonary resuscitation for a
median duration of 67 minutes (range 50-90 minutes). Four
additional patients who had support instituted primarily for
refractory hypotension also required brief periods of car-
diopulmonary resuscitation before the institution of
mechanical circulatory support.
Virology and Histology 
Virology titers were positive in 4 (27%) patients and viral
cultures were positive in 2 (13%) of the 15 patients.
Endomyocardial biopsy samples were submitted for the
polymerase chain reaction in 4 patients, with 1 having a pos-
itive reaction. With these techniques combined, viral
pathogens were isolated from 7 (47%) of the 15 patients and
are listed in Table 2. Twelve (80%) of the 15 patients under-
went cardiac catheterization with right ventricular endomy-
ocardial biopsy. One half of the patients undergoing biopsy
demonstrated unequivocal histologic evidence of myocardi-
tis per the Dallas criteria5 with both a mononuclear cellular
infiltrate and myocyte necrosis, and 4 (33%) of the 12
patients had nondiagnostic biopsy results (Table 3). The
presence of myocarditis on endomyocardial biopsy was not
associated with the need for subsequent transplantation or
survival (P = .58 and P = .91, respectively).
Immunotherapy 
Fourteen (93%) of 15 patients received some form of
immunotherapy, with 12 (80%) of 15 patients receiving
intravenous gamma globulin alone or in combination with
steroids. Eight (53%) of 15 patients received steroids alone
(2/8 patients) or in combination with gamma globulin (6/8
patients). These regimens were not standardized among the
centers, but in general 2 gm/kg of intravenous gamma glob-
ulin was administered whereas steroid administration con-
sisted of 10 mg/kg of intravenous methylprednisolone for 3
days followed by a tapered dose. Neither gamma globulin
nor steroid administration had a statistically significant
impact on the subsequent need for cardiac transplantation or
survival (data not shown).
Complications 
Complications were common in this critically ill population
of patients. No complication by organ system was signifi-
cantly associated with outcome (data not shown).
Hemorrhage from the cannulation site was the most com-
monly observed complication, occurring in 9 (60%) of 15
patients, and was statistically associated with transthoracic
cannulation (blood loss for chest cannulation 253 ± 55
mL/kg; blood loss for neck or groin cannulation 21 ± 68
Figure 1. Outcomes.
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mL/kg; P = .02). Seven (78%) of the 9 patients who had
hemorrhage from the cannulation site had transthoracic can-
nulas, and 2 (22%) patients cannulated via the groin had sig-
nificant cannulation site bleeding. In 1 (6.7%) patient who
was cannulated via groin vessels, a pseudoaneurysm of the
femoral artery developed and was treated with ultrasound-
guided compression and occlusion.
Seven (47%) patients had renal failure including 5
patients who required temporary dialysis and 2 patients who
demonstrated an increase in serum creatinine above 3
mg/dL. All surviving patients have recovered normal renal
function. Serious infection occurred in 4 (27%) patients and
directly contributed to 1 patient’s death from overwhelming
fungemia. Neurologic complications developed in 4 (27%)
patients, with 2 survivors. Each of these patients has experi-
enced substantial recovery, demonstrating grossly normal
neurologic function at present. Only 1 of the 4 patients who
demonstrated neurologic impairment at some point during
the hospitalization required cardiopulmonary resuscitation
before the institution of ECMO. All of the other 10 sur-
vivors had a neurologically benign course during hospital-
ization and remain in neurologically normal condition dur-
ing follow-up, despite the need for cardiopulmonary
resuscitation before ECMO in 5 of these patients.
Outcome 
The outcome for these 15 patients is shown in Figure 1,
which demonstrates 12 (80%) survivors. There was no sig-
nificant difference in survival between the two modalities
(ECMO 10/12 survivors, 83%; VAD 2/3 survivors, 67%; P
= .5). Mechanical circulatory support was used to manage
patients along two different pathways: expectantly (until
return of native ventricular function) and as a bridge to
transplantation. Nine (60%) of 15 patients had return of
native ventricular function allowing weaning from support,
with 7 (78%) survivors, and 6 (40%) patients were success-
fully bridged to cardiac transplantation, with 5 (83%) sur-
vivors. Patients bridged to transplantation were generally
encountered early in the series when it was believed that this
degree of ventricular dysfunction was likely to be irre-
versible and the decision to transplant was made early after
admission. Patients who received a heart transplant were
listed for transplantation the second day of support on aver-
age (range 1-4 days) and received a donor organ a median
of 6 days later (range 2-13 days). No patient died on support
while awaiting a donor organ. Four other patients were list-
ed for transplantation but had return of ventricular function
sufficient for weaning from mechanical circulatory support
(Table 1). There was no difference in duration of support,
days intubated, intensive care unit stay, or length of hospi-
talization between patients who underwent transplantation
and those who did not (Table 4).
Two patients who had recovery of ventricular function
sufficient to allow weaning from support died after support
was discontinued: one ECMO-supported patient died of
severe Candida sepsis 7 days after decannulation, and anoth-
er ECMO-supported patient died of Staphylococcus aureus
sepsis and severe anoxic encephalopathy within hours after
ECMO was terminated. No patient who had sufficient recov-
ery of myocardial function to allow weaning from support
died of cardiac failure after support was discontinued. One
patient died after transplantation: this VAD-supported patient
had significant anoxic brain injury and died of ventricular
fibrillation during a severe episode of acute rejection 2
months after VAD support was discontinued.
Despite profound ventricular dysfunction at the time of
presentation, all survivors who did not undergo transplanta-
tion now have normal ventricular function (Figure 2) after a
median follow-up of 1.1 years (range 0.9-5.3 years).
Interestingly, several of these patients still had significantly
reduced left ventricular fractional shortening at the time of
weaning from support. As indicators of recovery of end-organ
function, the serum creatinine (Figure 3) and aspartate amino-
transferase (Figure 4) are plotted throughout the clinical
course for 9 of the 12 survivors for whom this information is
available and for the 3 nonsurvivors. Despite significant ele-
vations of serum creatinine or aspartate aminotransferase in
several of the surviving patients, all survivors currently have
normal renal and hepatic function.
Statistical Analysis of the Impact of Clinical
Parameters on the Need for Transplantation and
Survival 
Of the clinical parameters that were examined (appendix),
only the central venous pressure at 24 hours of support had
TABLE 2. Viral pathogens
Virus No. of patients
Influenza 2
Coxsackie 1
Varicella zoster 1
Ebstein-Barr virus 1
Herpes simplex 1 1
Parainfluenza 1
Total 7
TABLE 3. Histology of endomyocardial biopsies
Patients
Histology No. %
Myocyte necrosis, cellular infiltrate 6 50
Myocyte necrosis 1 8.3
Cellular infiltrate 1 8.3
Nondiagnostic 4 33
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a statistically significant association with the lack of return
of native ventricular function ultimately leading to cardiac
transplantation: central venous pressure in patients undergo-
ing transplantation, 13.5 ± 0.7 mm Hg; central venous pres-
sure in patients not undergoing transplantation, 5.3 ± 1.2 (P
= .003). Of the clinical parameters examined to determine
their possible impact on survival (appendix), the serum cre-
atinine before support, the serum creatinine, aspartate
aminotransferase, alanine aminotransferase, and lactate at
24 hours of support, as well as the highest aspartate amino-
transferase and alanine aminotransferase achieved statistical
significance (Table 5).
Discussion
In its fulminant form, acute myocarditis has a rapidly pro-
gressive course quickly resulting in death due to profound
ventricular dysfunction.1,6 The present series is composed
of 15 children with clinically fulminant myocarditis whose
condition continued to deteriorate despite maximal medical
therapy. The favorable outcomes for these critically ill chil-
dren support aggressive measures during the acute phase of
this disease. Of special importance is the observation that
native ventricular function recovered to allow weaning from
support in the majority of these patients, with all of the sur-
vivors who did not undergo transplantation currently
demonstrating normal ventricular function.
Decision to Institute Support 
Indications. Determining the need for mechanical circu-
lation to support children with fulminant myocarditis is a
clinical decision. The rapid progression of the disease is an
immediate clue that medical therapy alone may be insuffi-
cient; all of the patients in this series had the onset of mild
constitutional symptoms precede cardiovascular collapse by
only hours to days. Diagnostic tests such as chest x-ray
films and electrocardiograms provide supportive evidence
for the diagnosis but are nonspecific. The demonstration of
profound ventricular dysfunction on echocardiography
identifies patients at risk, but the clinical status of the patient
remains the critical determinant of whether to institute
ECMO or VAD support.
The most important factor leading to the decision to insti-
tute mechanical circulatory support is the observation that
medical treatment is failing. Increasing inotropic require-
ments, accompanied by evidence of inadequate cardiac output
such as poor cutaneous perfusion, oliguria, and systemic aci-
dosis are unlikely to be reversed by further medical manage-
ment in this condition. The need for excessive inotropic doses
accompanied by significant ventricular ectopy is a particular-
ly dangerous combination for which mechanical circulatory
support should be strongly considered. Cardiac arrest, even of
brief duration, is an ominous sign indicating that circulatory
support should be considered. Overall, an aggressive stance
toward the institution of mechanical circulatory support
should be taken in these patients because of their tendency
toward unpredictable and rapid deterioration.
Management Issues During Support  
Choice of device and site of cannulation. We have pre-
viously reported that either ECMO or a VAD may be used
to successfully support children with a wide range of car-
diac diseases.4 In terms of the site of cannulation, ECMO
provides greater flexibility because vessels in the neck,
groin, or chest are used, whereas the use of a VAD necessi-
tates transthoracic cannulation. In the present study, the
institution of ECMO or VAD support via transthoracic can-
Cardiopulmonary Support and Physiology Duncan et al
Figure 2. Fractional shortening for all 7 survivors who did not
undergo transplantation determined when support was initiated,
at the time of discontinuation of support, and at the time of the
most recent follow-up.
Figure 3. Serum creatinine for 9 surviving patients and 3 nonsur-
viving patients at the time of support initiation, 24 hours after sup-
port was initiated, the highest level attained during the hospital-
ization, and at the latest determination.
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nulation led to significantly more bleeding complications
and introduced an additional source of infection. With these
factors in mind, we prefer ECMO for children who require
support for myocarditis because of its ability to be institut-
ed via peripheral cannulation and the presence of an oxy-
genator for use in patients with hypoxemia. For the institu-
tion of ECMO, we prefer neck cannulation for neonates and
infants. For older children and adolescents, we prefer
femoral cannulation to avoid cerebral ischemia that may
result from carotid cannulation.
For ECMO-supported patients, the development of left-
sided cardiac distention must be assiduously avoided by
monitoring left-sided filling pressures and the echocardio-
graphic appearance of the left ventricle. If left ventricular
distention is documented, decompression should be aggres-
sively performed. For patients who are cannulated via the
transthoracic route, direct venting of the left ventricle by
placement of a drainage cannula via the left atrial
appendage or right superior pulmonary vein can be easily
performed. For ECMO-supported patients cannulated via
peripheral vessels, balloon atrial septostomy, performed in
the cardiac catheterization laboratory or at the bedside under
echocardiographic guidance, is an effective means of left-
sided decompression for patients without an existing ster-
notomy.7,8 In the present series, 7 (58%) of the 12 patients
supported with ECMO required some form of left-sided
cardiac decompression.
Optimization of end-organ function. In the present
study, elevations of markers of end-organ function such as
creatinine, liver enzymes, and serum lactate before support
and early after support was instituted were predictive of
increased mortality. Early elevations of these markers iden-
tify children with an aggressive disease process, as well as
reflecting the effectiveness of resuscitative efforts. The best
approach to optimize end-organ function in patients who
require mechanical circulatory support is to institute support
early, before extended periods of low cardiac output or car-
diac arrest. Measurement of markers of end-organ function
may provide prognostic information in these children as
well as reflecting the timeliness of the establishment of cir-
culatory support.
Endomyocardial biopsy. Two thirds of the patients in
this study had unequivocal or borderline evidence of lym-
phocytic myocarditis according to the Dallas criteria, simi-
lar to the 20% to 60% of patients with positive biopsy
results reported in other series.5,9-11 Factors leading to neg-
ative biopsy results in these children have been previously
described and include sampling error and the possibility that
humoral rather than cellular mediators are responsible for
the clinical condition.10,12 All 3 reporting centers advocate
performing endomyocardial biopsy during the course of
acute myocarditis to rule out other causes of profound ven-
tricular dysfunction such as metabolic causes of dilated car-
diomyopathy. This is especially important in the pediatric
population because metabolic causes of cardiomyopathy
may require specific treatment and may be inherited, with
implications for family planning. Currently, children who
require mechanical circulatory support with histologic find-
ings of acute myocarditis would be managed expectantly
with hope for the eventual return of native ventricular func-
tion, whereas patients with histologic findings of cardiomy-
opathy who require ECMO or VAD would be urgently list-
ed for transplantation.
Immunotherapy. Fourteen (93%) of the 15 patients in
this series received some form of immunotherapy, with the
majority (12 patients) receiving intravenous gamma globu-
lin. We believe that the use of intravenous gamma globulin
is of potential benefit in patients with acute myocarditis and
is associated with relatively few risks.13 The benefit of this
therapy cannot be clearly demonstrated in this small popu-
lation; however, the low overall mortality and the return of
native ventricular function in a significant number of
patients in this series suggests that gamma globulin admin-
istration may have contributed positively. On the basis of the
existing data, we do not advocate the routine use of steroids
in the treatment of this condition.14,15 In fact, steroid admin-
istration during the acute phase of the disease has been
shown experimentally to impair viral clearance and
TABLE 4.  Duration of mechanical circulatory support, intu-
bation, intensive care unit stay, and hospitalization for
patients having transplantation and those not having trans-
plantation
No transplant Transplant 
Duration of: (n = 9) (n = 6) P value
Mechanical circulatory 5.8 (4.8-16.7) 5.6 (2-13.5) .52
support
Intubation 11 (9-45) 19 (3-38) .31
Intensive care unit stay 15 (9-75) 24 (8-77) .34
Total hospital stay 25 (9-106) 39 (15-77) .32
Durations are expressed in days. All values represent median (range).
TABLE 5.  Association of clinical parameters with survival
Parameter Survivors Nonsurvivors P value
Serum creatinine before 0.9 ± 0.5 2.6 ± 0.4 .001
support (mg/dL)
AST at 24 hours (U/L) 986 ± 1678 4569 ± 5012 .05
ALT at 24 hours (U/L) 444 ± 987 3851 ± 3034 .005
Lactate at 24 hours 2.1 ± 1.1 8.9 ± 1.5 .02
(mg/dL)
Highest AST (mg/dL) 1246 ± 1783 7802 ± 8449 .02
Highest ALT (mg/dL) 611 ± 1045 3373 ± 3003 .02
AST, Serum aspartate aminotransferase; ALT, alanine aminotransferase.
All values represent mean ± standard deviation.
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decrease survival.16,17 The merits of any immunotherapeu-
tic regimen in patients with acute myocarditis will be best
addressed by prospective randomized trials in larger num-
bers of patients.
Outlook for Pediatric Patients With Clinically
Fulminant Myocarditis
Return of native ventricular function versus bridge to
transplantation. The importance of the present study lies
chiefly in demonstrating excellent survival in even the most
severely affected children with few chronic complications.
An equally significant finding from the present study is the
reversibility of myocardial dysfunction demonstrated by
these patients. Historically, studies have suggested that
dilated cardiomyopathy would be expected to develop in a
significant percentage of children with acute myocarditis
with the ultimate need for cardiac transplantation.6 Our
findings suggest that the present pediatric population with
acute, fulminant myocarditis behaves differently, with an
overall favorable outcome and a significant degree of dis-
ease reversibility if successfully supported during the acute
phase of illness.
These results support those in a recent study by
McCarthy and coworkers,18 who described the superior
long-term outcome of a group of adult patients with fulmi-
nant myocarditis compared with patients who had acute,
nonfulminant myocarditis. Patients with fulminant disease
presented with severe hemodynamic compromise, distinct
onset of heart failure symptoms, and the presence of a viral
illness within 2 weeks of hospitalization. All patients with
fulminant myocarditis were receiving high doses of intra-
venous inotropic agents, but only 2 of 15 patients required
mechanical circulatory support. Patients classified with
acute, nonfulminant myocarditis had a clinical picture that
was less severe with an indistinct onset. Despite being more
critically ill acutely, the patients with fulminant myocarditis
had a better long-term outcome, with 93% of these patients
being alive without transplantation after 11 years of follow-
up, compared with only 45% of patients with acute, nonful-
minant myocarditis.
The reasons for better long-term outcomes and a
decreased incidence of progression to dilated cardiomyopa-
thy in patients who are the most severely affected with
myocarditis remain unexplained. Proposed mechanisms for
this clinical paradox include differences in viral agents lead-
ing to fulminant versus nonfulminant forms of myocarditis,
differences in host response to viral infection between the
two entities, and the possibility that fulminant myocarditis
is due to an autoimmune disorder.18-20 In the present study,
salutary effects of mechanical circulatory support may have
contributed to the improved long-term outcomes in these
children. In patients with dilated cardiomyopathy, pro-
longed mechanical circulatory support may result in ulti-
mate recovery of ventricular function because of favorable
influences on the neurohormonal cardiovascular milieu and
unloading of the left ventricle resulting in normalization of
ventricular geometry—a process termed reversible remodel-
ing.21 We believe that the institution of mechanical circula-
tory support in patients with acute fulminant myocarditis
can favorably affect these same factors, resulting in ventric-
ular recovery over a much shorter time course—a process
that we have termed rapid reversible remodeling. In these
most severe cases of myocarditis, mechanical circulatory
support provides the ultimate form of physiologic rest, sim-
ilar to simple bed rest and oxygen used to support less
severe cases. It is compelling to speculate that normalization
of ventricular geometry and function by the early institution
of support in the present study may have helped to prevent
the development of dilated cardiomyopathy.
We agree with the conclusion of McCarthy and cowork-
ers18 that native ventricular function may ultimately be expect-
ed to return in most patients with fulminant myocarditis. This
raises questions as to the role of transplantation in the fulmi-
nant form of this disease. The present study was not a ran-
domized trial of expectant management versus bridge to trans-
plantation in these patients. In the present series, patients were
listed for transplantation according to the preferences and
practices of the physicians in each institution; they were gen-
erally listed early (median of 2 days) and received a donor
organ quickly (median of 6 days after listing). Currently, all 3
of the participating centers would adopt a more expectant
course of management to give these patients a greater chance
for return of native ventricular function.
Cardiopulmonary Support and Physiology Duncan et al
Figure 4. Serum aspartate aminotransferase for 9 surviving
patients and 3 nonsurviving patients at the time of support initia-
tion, 24 hours after support was initiated, the highest level
attained during the hospitalization, and at the most recent deter-
mination.
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On the basis of these results, the optimal approach for
children with acute fulminant myocarditis may be to provide
mechanical circulatory support, even if required for pro-
longed periods, in anticipation of eventual ventricular recov-
ery. Previous reports have documented full return of ventric-
ular function in young adults with myocarditis after weeks or
months of mechanical support.22,23 A limitation of this
approach for children is that ECMO and centrifugal VAD
systems, which are currently available in the United States
for pediatric patients, are not suitable for such extended peri-
ods of support. Pulsatile paracorporeal or implantable sys-
tems that allow extended periods of support have been used
successfully in pediatric patients in Europe and have demon-
strated the feasibility of this approach.24,25 Prolonged
mechanical circulatory support in a larger number of pedi-
atric patients with fulminant myocarditis may reveal that the
capability of supporting these children for weeks or months
will allow return of native ventricular function, thereby
avoiding transplantation in the majority of these children.
We appreciate the statistical consultation of Geoffrey L.
Rosenthal, MD, PhD.
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Appendix  
Clinical Parameters Tested for Their Possible
Association With (1) Return of Native Ventricular
Function Versus the Need for Transplantation and (2)
Survival
Demographics
Sex
Weight
Age
Hemodynamics (before support and at 24 hours of support)
Central venous pressure
Right atrial pressure
Left atrial pressure
Systolic blood pressure
Diastolic blood pressure
Mean arterial blood pressure
Arterial blood gases (before support and at 24 hours of support)
PO2
PCO2
pH
Total serum bicarbonate
Mixed venous oxygen saturation
Ventilator settings (before support and at 24 hours of support)
FIO2
Ventilatory rate
Site of cannulation
Neck or groin
Chest
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ED
ITO
RIA
L
CPS
G
TS
A
CD
ET
CSP
TX
Complication by organ system
Cardiovascular
Pulmonary
Gastrointestinal
Renal
Infectious
Hemorrhagic
Blood loss
Estimated blood loss on support
Number of reexplorations for bleeding
Doses of inotropic agents: (before support and at 24 hours of
support)
Dopamine
Amrinone
Dobutamine
Epinephrine
Cardiac function (determined by ECHO before the institution
of support)
Fractional shortening
Ejection fraction
Determinants of end-organ function (before support, at 24
hours of support, the highest level during hospitalization,
and the most recent level)
Serum creatinine
Serum aspartate aminotransferase
Serum alanine aminotransferase
Serum lactate
Serum bilirubin
Miscellaneous
Urine output (before support)
Urine output (over the first 24 hours of support)
Cardiopulmonary resuscitation before support 
Duration of cardiopulmonary resuscitation
Results of endomyocardial biopsy
Left ventricular decompression
Use of gamma globulin
Use of steroids
Cardiopulmonary Support and Physiology Duncan et al
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